aTyr Pharma is a clinical stage biotechnology company leveraging evolutionary intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation. Our lead therapeutic candidate is efzofitimod, a first-in-class biologic immunomodulator in clinical development for the treatment of interstitial lung disease (ILD), a group of immune-mediated disorders that can cause chronic inflammation and progressive fibrosis, or scarring, of the lungs. We are currently investigating efzofitimod in the global Phase 3 EFZO-FIT™ study in patients with pulmonary sarcoidosis, a major form of ILD, and the Phase 2 EFZO-CONNECT™ study in patients with systemic sclerosis (SSc, or scleroderma)-related ILD. Efzofitimod has received U.S. Food and Drug Administration (FDA) and E.U. orphan drug designations and U.S. FDA Fast Track designations for both sarcoidosis and SSc. We also have a partnership with Kyorin Pharmaceutical, Co., Ltd., with a total deal value up to $175m, for the development and commercialization of efzofitimod for ILD in Japan. In addition to efzofitimod, we have a pipeline of therapeutic candidates derived from our tRNA synthetase platform targeting inflammation and fibrosis.